Oncology

Back to articles

First JAK inhibitor improves symptoms, but not survival, in myelofibrosis

KEY POINT

Ruxolitinib (Jakafi—Incyte), the first agent in the new Janus kinase (JAK) inhibitor class, was approved by FDA in 2011 for the treatment of patients with intermediate- or high-risk myelofibrosis, a disorder that has been associated with dysregulated signaling in the JAK pathway.

SOURCES

Harrison D et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98. 

Verstovsek S et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807. 

Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms [editorial]. N Engl J Med. 2012;366:844–6.